2026 Q1 -tulosraportti
91 päivää sitten
‧43 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·6 t sittenSome input from Ulrich before Monday's presentation: https://biostock.se/en/2026/08/curasight-letting-the-data-guide-utreat-development/
·11 t sitten☢️ Trial A → Trial B → one combined clinical answer After H1, there has been a lot of focus on why Curasight chooses to push mBBB-topline and instead report mBBB and uBBB combined. Immediately, it might seem like a strange decision. But looking at how the trial has actually developed, the decision makes good clinical sense. Trial A: The original mBBB study. Can uTREAT deliver high tumor uptake, retention, and therapeutically relevant dosimetry with mannitol/BBB disruption? Along the way, data raised a new question: What happens if mannitol and BBB disruption are removed? Trial B: The new uBBB study. Same uTREAT, same disease, and same basic treatment principle – but without mannitol. Curasight itself describes that the comparison with the first cohort should provide information about the effect of BBB disruption. uBBB is not just a new, isolated dataset. It can be used to better understand the mBBB result: • How much does mannitol contribute to tumor uptake? • What happens to retention and biodistribution? • How much does the dosimetry change? • Can a therapeutically relevant tumor dose be achieved without BBB disruption? • And which administration form makes the most sense going forward? A large part of the value of uBBB lies precisely in the comparison with mBBB, because it shows what the change in the trial setup, with or without mannitol/BBB disruption, means for uTREAT’s tumor delivery and dosimetry. Therefore, it makes the most sense to wait for both datasets and present: mBBB → uBBB → direct comparison → combined clinical conclusion → next step. This also aligns well with management's statement that the protocol change should create a “more robust clinical dataset” and a better basis for the design of the next phase. If uBBB shows that a similarly relevant tumor delivery can be achieved without mannitol, the mBBB approach with BBB disruption could potentially become redundant as the preferred administration form. mBBB has thus laid the foundation for uTREAT. uBBB potentially shows that it can be done more simply and Curasight gets answers on how uTREAT is best delivered to the patient. Monday we listen, does Andreas say anything about mBBB-topline?...👂 Data is King - we need to see it! ⚡
What about the tumor types that don't hide behind BBB. Lung, bowel and prostate. It is not necessary with mannitol for the radiation treatment to reach them. Are there no trials on them??
·12 t sittenTherefore, it drops to a price of 5. Early 2027. D 1. The market already begins in the autumn to expect an emission. 2. The price may be pushed down towards 8–9 kr. 3. The emission must be carried out with an additional 20–30 % discount, for example at 6–7 kr. 4. If the capital only lasts for another 9–12 months, the market immediately fears another emission. Thus, in a stressed scenario, the share can briefly hit 5–8 kr., even without bad clinical data. If at the same time there is another delay or weak results, the fall can be greater.Overall, I am approximately 12.760 kr. up since purchase, corresponding to +3.01 %. * Total invested amount: approx. 424.125 kr. * Current value: 436.885 kr. * Unrealized gain: approx. 12.760 kr. The strange percentage is probably due to me having deposited money and withdrawn/moved almost the entire portfolio several times. The graph shows repeated drops to almost zero. Nordnet's time-weighted return is therefore linked together period by period, and losses at a time when the portfolio was small can have enormous percentage significance. The economically relevant status therefore appears to be: * Current equity: 448.785 kr. * Total historical result: approximately −9.895 kr. * Real total return measured against net deposits: approximately −2.2 %, if net deposits are approximately 458.680 kr. * Current shares isolated: +12.760 kr. / +3.01 % So yes: −63.5 % gives a very wrong picture of your actual financial development. −9.895 kr. is far more relevant. For a completely precise result since inception, we need Nordnet's transaction report/account statement with all deposits, withdrawals, trades, dividends and currency costs.
·13 t sittenI am happy for your positive feeds and followed up. Have bought up. Can't someone just give me peace of mind and confirm it was good 😅
Yes, you just need to be patient. Don't let people's posts panic you. Read up on everything. I have done that and welcomed the dip. It will surely come up. Patience can pay off. Just my opinion, no recommendation from here. I am holding and I am holding for a long time.- ·13 t sittenOh dear, looks dismalManagement has already shown this when they raised the 20. Mio. The worrying thing is: They are postponing both significant readings until the first half of 2027. The explanation is relatively vague: "uncertainty regarding the final patient recruitment". uTREAT simultaneously requires a protocol amendment and regulatory approval. The delay comes at a time when the company's financing is under pressure. * "First half of 2027" is a very broad interval and can in practice mean June 2027.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
91 päivää sitten
‧43 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6 t sittenSome input from Ulrich before Monday's presentation: https://biostock.se/en/2026/08/curasight-letting-the-data-guide-utreat-development/
- ·11 t sitten☢️ Trial A → Trial B → one combined clinical answer After H1, there has been a lot of focus on why Curasight chooses to push mBBB-topline and instead report mBBB and uBBB combined. Immediately, it might seem like a strange decision. But looking at how the trial has actually developed, the decision makes good clinical sense. Trial A: The original mBBB study. Can uTREAT deliver high tumor uptake, retention, and therapeutically relevant dosimetry with mannitol/BBB disruption? Along the way, data raised a new question: What happens if mannitol and BBB disruption are removed? Trial B: The new uBBB study. Same uTREAT, same disease, and same basic treatment principle – but without mannitol. Curasight itself describes that the comparison with the first cohort should provide information about the effect of BBB disruption. uBBB is not just a new, isolated dataset. It can be used to better understand the mBBB result: • How much does mannitol contribute to tumor uptake? • What happens to retention and biodistribution? • How much does the dosimetry change? • Can a therapeutically relevant tumor dose be achieved without BBB disruption? • And which administration form makes the most sense going forward? A large part of the value of uBBB lies precisely in the comparison with mBBB, because it shows what the change in the trial setup, with or without mannitol/BBB disruption, means for uTREAT’s tumor delivery and dosimetry. Therefore, it makes the most sense to wait for both datasets and present: mBBB → uBBB → direct comparison → combined clinical conclusion → next step. This also aligns well with management's statement that the protocol change should create a “more robust clinical dataset” and a better basis for the design of the next phase. If uBBB shows that a similarly relevant tumor delivery can be achieved without mannitol, the mBBB approach with BBB disruption could potentially become redundant as the preferred administration form. mBBB has thus laid the foundation for uTREAT. uBBB potentially shows that it can be done more simply and Curasight gets answers on how uTREAT is best delivered to the patient. Monday we listen, does Andreas say anything about mBBB-topline?...👂 Data is King - we need to see it! ⚡What about the tumor types that don't hide behind BBB. Lung, bowel and prostate. It is not necessary with mannitol for the radiation treatment to reach them. Are there no trials on them??
- ·12 t sittenTherefore, it drops to a price of 5. Early 2027. D 1. The market already begins in the autumn to expect an emission. 2. The price may be pushed down towards 8–9 kr. 3. The emission must be carried out with an additional 20–30 % discount, for example at 6–7 kr. 4. If the capital only lasts for another 9–12 months, the market immediately fears another emission. Thus, in a stressed scenario, the share can briefly hit 5–8 kr., even without bad clinical data. If at the same time there is another delay or weak results, the fall can be greater.Overall, I am approximately 12.760 kr. up since purchase, corresponding to +3.01 %. * Total invested amount: approx. 424.125 kr. * Current value: 436.885 kr. * Unrealized gain: approx. 12.760 kr. The strange percentage is probably due to me having deposited money and withdrawn/moved almost the entire portfolio several times. The graph shows repeated drops to almost zero. Nordnet's time-weighted return is therefore linked together period by period, and losses at a time when the portfolio was small can have enormous percentage significance. The economically relevant status therefore appears to be: * Current equity: 448.785 kr. * Total historical result: approximately −9.895 kr. * Real total return measured against net deposits: approximately −2.2 %, if net deposits are approximately 458.680 kr. * Current shares isolated: +12.760 kr. / +3.01 % So yes: −63.5 % gives a very wrong picture of your actual financial development. −9.895 kr. is far more relevant. For a completely precise result since inception, we need Nordnet's transaction report/account statement with all deposits, withdrawals, trades, dividends and currency costs.
- ·13 t sittenI am happy for your positive feeds and followed up. Have bought up. Can't someone just give me peace of mind and confirm it was good 😅Yes, you just need to be patient. Don't let people's posts panic you. Read up on everything. I have done that and welcomed the dip. It will surely come up. Patience can pay off. Just my opinion, no recommendation from here. I am holding and I am holding for a long time.
- ·13 t sittenOh dear, looks dismalManagement has already shown this when they raised the 20. Mio. The worrying thing is: They are postponing both significant readings until the first half of 2027. The explanation is relatively vague: "uncertainty regarding the final patient recruitment". uTREAT simultaneously requires a protocol amendment and regulatory approval. The delay comes at a time when the company's financing is under pressure. * "First half of 2027" is a very broad interval and can in practice mean June 2027.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
2026 Q1 -tulosraportti
91 päivää sitten
‧43 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6 t sittenSome input from Ulrich before Monday's presentation: https://biostock.se/en/2026/08/curasight-letting-the-data-guide-utreat-development/
- ·11 t sitten☢️ Trial A → Trial B → one combined clinical answer After H1, there has been a lot of focus on why Curasight chooses to push mBBB-topline and instead report mBBB and uBBB combined. Immediately, it might seem like a strange decision. But looking at how the trial has actually developed, the decision makes good clinical sense. Trial A: The original mBBB study. Can uTREAT deliver high tumor uptake, retention, and therapeutically relevant dosimetry with mannitol/BBB disruption? Along the way, data raised a new question: What happens if mannitol and BBB disruption are removed? Trial B: The new uBBB study. Same uTREAT, same disease, and same basic treatment principle – but without mannitol. Curasight itself describes that the comparison with the first cohort should provide information about the effect of BBB disruption. uBBB is not just a new, isolated dataset. It can be used to better understand the mBBB result: • How much does mannitol contribute to tumor uptake? • What happens to retention and biodistribution? • How much does the dosimetry change? • Can a therapeutically relevant tumor dose be achieved without BBB disruption? • And which administration form makes the most sense going forward? A large part of the value of uBBB lies precisely in the comparison with mBBB, because it shows what the change in the trial setup, with or without mannitol/BBB disruption, means for uTREAT’s tumor delivery and dosimetry. Therefore, it makes the most sense to wait for both datasets and present: mBBB → uBBB → direct comparison → combined clinical conclusion → next step. This also aligns well with management's statement that the protocol change should create a “more robust clinical dataset” and a better basis for the design of the next phase. If uBBB shows that a similarly relevant tumor delivery can be achieved without mannitol, the mBBB approach with BBB disruption could potentially become redundant as the preferred administration form. mBBB has thus laid the foundation for uTREAT. uBBB potentially shows that it can be done more simply and Curasight gets answers on how uTREAT is best delivered to the patient. Monday we listen, does Andreas say anything about mBBB-topline?...👂 Data is King - we need to see it! ⚡What about the tumor types that don't hide behind BBB. Lung, bowel and prostate. It is not necessary with mannitol for the radiation treatment to reach them. Are there no trials on them??
- ·12 t sittenTherefore, it drops to a price of 5. Early 2027. D 1. The market already begins in the autumn to expect an emission. 2. The price may be pushed down towards 8–9 kr. 3. The emission must be carried out with an additional 20–30 % discount, for example at 6–7 kr. 4. If the capital only lasts for another 9–12 months, the market immediately fears another emission. Thus, in a stressed scenario, the share can briefly hit 5–8 kr., even without bad clinical data. If at the same time there is another delay or weak results, the fall can be greater.Overall, I am approximately 12.760 kr. up since purchase, corresponding to +3.01 %. * Total invested amount: approx. 424.125 kr. * Current value: 436.885 kr. * Unrealized gain: approx. 12.760 kr. The strange percentage is probably due to me having deposited money and withdrawn/moved almost the entire portfolio several times. The graph shows repeated drops to almost zero. Nordnet's time-weighted return is therefore linked together period by period, and losses at a time when the portfolio was small can have enormous percentage significance. The economically relevant status therefore appears to be: * Current equity: 448.785 kr. * Total historical result: approximately −9.895 kr. * Real total return measured against net deposits: approximately −2.2 %, if net deposits are approximately 458.680 kr. * Current shares isolated: +12.760 kr. / +3.01 % So yes: −63.5 % gives a very wrong picture of your actual financial development. −9.895 kr. is far more relevant. For a completely precise result since inception, we need Nordnet's transaction report/account statement with all deposits, withdrawals, trades, dividends and currency costs.
- ·13 t sittenI am happy for your positive feeds and followed up. Have bought up. Can't someone just give me peace of mind and confirm it was good 😅Yes, you just need to be patient. Don't let people's posts panic you. Read up on everything. I have done that and welcomed the dip. It will surely come up. Patience can pay off. Just my opinion, no recommendation from here. I am holding and I am holding for a long time.
- ·13 t sittenOh dear, looks dismalManagement has already shown this when they raised the 20. Mio. The worrying thing is: They are postponing both significant readings until the first half of 2027. The explanation is relatively vague: "uncertainty regarding the final patient recruitment". uTREAT simultaneously requires a protocol amendment and regulatory approval. The delay comes at a time when the company's financing is under pressure. * "First half of 2027" is a very broad interval and can in practice mean June 2027.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt